Table 4.

The benefit of folic acid supplementation and adenoma risk in participants with differing baseline plasma folate levels (N = 384)

Baseline plasma folatea (<4.27 ng/mL)Baseline plasma folate (≥4.27 ng/mL)
n = 118n = 266
No CRA (n = 76)CRA occurred (n = 42)No CRA (n = 244)CRA occurred (n = 22)
Plasma folate in baseline2.49 ± 1.512.61 ± 1.347.07 ± 3.786.08 ± 2.57
Plasma folate after follow-up9.22 ± 2.964.65 ± 1.758.14 ± 3.106.86 ± 2.24
P value<0.001<0.001<0.010.85

NOTE: All data are shown in mean ± SD.

Abbreviation: n, number of participants.

  • aRR, 6.13; 95% CI, 3.44–10.91, which means participants with low baseline plasma folate may have a high risk of CRA.